Logo image of EGOX

NEXT.E.GO NV (EGOX) Stock Fundamental Analysis

NASDAQ:EGOX - Nasdaq - NL0015001M17 - Common Stock - Currency: USD

0.0306  +0 (+10.87%)

After market: 0.032 +0 (+4.58%)

Fundamental Rating

0

Overall EGOX gets a fundamental rating of 0 out of 10. We evaluated EGOX against 39 industry peers in the Automobiles industry. Both the profitability and financial health of EGOX have multiple concerns. EGOX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EGOX has reported negative net income.
In the past year EGOX has reported a negative cash flow from operations.
EGOX Yearly Net Income VS EBIT VS OCF VS FCFEGOX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -1M -2M -3M -4M

1.2 Ratios

With a Return On Assets value of -25.68%, EGOX perfoms like the industry average, outperforming 41.03% of the companies in the same industry.
Industry RankSector Rank
ROA -25.68%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EGOX Yearly ROA, ROE, ROICEGOX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 -5 -10 -15 -20 -25

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EGOX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EGOX Yearly Profit, Operating, Gross MarginsEGOX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for EGOX has been reduced compared to 1 year ago.
There is no outstanding debt for EGOX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EGOX Yearly Shares OutstandingEGOX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 10M 20M 30M
EGOX Yearly Total Debt VS Total AssetsEGOX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -4.80, we must say that EGOX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.80, EGOX is doing worse than 69.23% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.8
ROIC/WACCN/A
WACCN/A
EGOX Yearly LT Debt VS Equity VS FCFEGOX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 0 50M 100M 150M 200M

2.3 Liquidity

EGOX has a Current Ratio of 0.53. This is a bad value and indicates that EGOX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.53, EGOX is not doing good in the industry: 84.62% of the companies in the same industry are doing better.
EGOX has a Quick Ratio of 0.53. This is a bad value and indicates that EGOX is not financially healthy enough and could expect problems in meeting its short term obligations.
EGOX has a Quick ratio of 0.53. This is in the lower half of the industry: EGOX underperforms 74.36% of its industry peers.
Industry RankSector Rank
Current Ratio 0.53
Quick Ratio 0.53
EGOX Yearly Current Assets VS Current LiabilitesEGOX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 0 0 0 0 0

More info and screens

0

3. Growth

3.1 Past

The earnings per share for EGOX have decreased strongly by -216.99% in the last year.
EPS 1Y (TTM)-216.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1009.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EGOX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EGOX Price Earnings VS Forward Price EarningsEGOX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EGOX Per share dataEGOX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

EGOX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEXT.E.GO NV

NASDAQ:EGOX (4/30/2024, 10:50:34 PM)

After market: 0.032 +0 (+4.58%)

0.0306

+0 (+10.87%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupAutomobiles & Components
GICS IndustryAutomobiles
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap284.32K
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0
BVpS-1.68
TBVpS-1.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.68%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.53
Quick Ratio 0.53
Altman-Z -4.8
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-216.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1009.45%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-101.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.39%
OCF growth 3YN/A
OCF growth 5YN/A